Yonhap Infomax NewsCelltrion has signed an exclusive licensing deal with US biotech Kaigene, securing two antibody-based drug candidates for autoimmune diseases in a deal worth up to 1.062 trillion won ($770 million), further strengthening its position in innovative drug development.
#YonhapInfomax #Celltrion #Kaigene #AntibodyTherapeutics #AutoimmuneDisease #LicensingDeal #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89053
#YonhapInfomax #Celltrion #Kaigene #AntibodyTherapeutics #AutoimmuneDisease #LicensingDeal #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89053
Celltrion Secures Two Antibody-Based Drug Candidates Through Exclusive Licensing Deal With US Biotech
Celltrion has signed an exclusive licensing deal with US biotech Kaigene, securing two antibody-based drug candidates for autoimmune diseases in a deal worth up to 1.062 trillion won ($770 million), further strengthening its position in innovative drug development.